Sunitinib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8331 publications

Apatinib combined with capecitabine plus temozolomide versus sunitinib in advanced gastroenteropancreatic neuroendocrine tumours: a propensity score-matched real-world study.

Apatinib combined with capecitabine plus temozolomide versus sunitinib in advanced gastroenteropancreatic neuroendocrine tumours: a propensity score-matched real-world study.

Journal: Journal of chemotherapy (Florence, Italy)

Published: June 13, 2026

Sex-Specific Adverse Events and Cardiovascular Toxicity of Cabozantinib in Renal Cell Carcinoma: A Nine-Year Pharmacovigilance Study.

Sex-Specific Adverse Events and Cardiovascular Toxicity of Cabozantinib in Renal Cell Carcinoma: A Nine-Year Pharmacovigilance Study.

Journal: Cancer investigation

Published: May 29, 2026

A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implications.

A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implications.

Journal: Future science OA

Published: May 15, 2026

FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer.

FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer.

Journal: Pharmacological research

Published: May 05, 2026

LGALS1 promotes the malignant progression and sunitinib resistance of clear cell renal cell carcinoma by reprogramming fatty acid metabolism.

LGALS1 promotes the malignant progression and sunitinib resistance of clear cell renal cell carcinoma by reprogramming fatty acid metabolism.

Journal: International immunopharmacology

Published: April 26, 2026

Retraction Note: The anticancer drug sunitinib promotes autophagy and protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration.

Retraction Note: The anticancer drug sunitinib promotes autophagy and protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration.

Journal: Journal of neurovirology

Published: April 23, 2026

Recurrent intracranial hemorrhage without brain metastasis after VEGFR TKI rechallenge in metastatic renal cell carcinoma: a case report and literature review.

Recurrent intracranial hemorrhage without brain metastasis after VEGFR TKI rechallenge in metastatic renal cell carcinoma: a case report and literature review.

Journal: Frontiers in oncology

Published: April 17, 2026

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Journal: JAMA network open

Published: April 15, 2026

ALOX5 mediates sunitinib resistance in renal cell carcinoma by reprogramming lipid metabolism through the p38/ERK/PPARα axis.

ALOX5 mediates sunitinib resistance in renal cell carcinoma by reprogramming lipid metabolism through the p38/ERK/PPARα axis.

Journal: International immunopharmacology

Published: April 14, 2026

Optimizing Sequential Targeted Therapies in Advanced Renal Cell Carcinoma Using Patient-Derived Orthotopic Xenograft Mouse Avatars.

Optimizing Sequential Targeted Therapies in Advanced Renal Cell Carcinoma Using Patient-Derived Orthotopic Xenograft Mouse Avatars.

Journal: Cancers

Published: April 12, 2026

Molecular mechanisms and therapeutic targets of traditional Chinese Medicine compounds in renal cell carcinoma: A comprehensive narrative review.

Molecular mechanisms and therapeutic targets of traditional Chinese Medicine compounds in renal cell carcinoma: A comprehensive narrative review.

Journal: Journal of ethnopharmacology

Published: April 11, 2026

Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis.

Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis.

Journal: Inquiry : a journal of medical care organization, provision and financing

Published: April 09, 2026

Showing 1-12 of 8,331

Last Updated: 06/30/2026